Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC‐EHRA EURObservational research programme in atrial fibrillation general long‐term registry
Fiche du document
2022
- ISIDORE Id: 10670/1.08d927...
- hal: hal-03677338
- doi: 10.1111/eci.13773
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1111/eci.13773
Sujets proches
Death--Philosophy Dying End of lifeCiter ce document
T Pitt‐kerby et al., « Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC‐EHRA EURObservational research programme in atrial fibrillation general long‐term registry », HALSHS : archive ouverte en Sciences de l’Homme et de la Société, ID : 10.1111/eci.13773
Métriques
Partage / Export
Résumé
Background: The management of patients with atrial fibrillation (AF) and malignancy is challenging given the paucity of evidence supporting their appropriate clinical management. Purpose: To evaluate the outcomes of patients with active or prior malignancy in a contemporary cohort of European AF patients. Methods: Patients enrolled in the EURObservational Research Programme in AF General Long-Term Registry were categorized into 3 categories: No Malignancy (NoMal), Prior Malignancy (PriorMal) and Active Malignancy (ActiveMal). The primary outcomes were all-cause death and the composite outcome MACE. Results: A total of 10 383 patients were analysed. Of these, 9597 (92.4%) were NoMal patients, 577 (5.6%) PriorMal and 209 (2%) ActiveMal. Lack of any antithrombotic treatment was more prevalent in ActiveMal patients (12.4%) as compared to other groups (5.0% vs 6.3% for PriorMal and NoMal, p
